A 6-week, multicenter, double-blind, placebo-controlled phase 3 clinical trial found that high-dose centanafadine (CTN), a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), significantly improved symptoms of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 12 years compared with placebo. Results of the study were published in Pediatrics Open Science.